← All Research
November 6, 2026·3 min read·Erick Rodriguez, Founder

What Happens When You Stop a GLP-1?

Reviewer: CTO, November 6, 2026
Disclosure: PeptidesGPT and Peptides Intelligence share ownership. Nothing here is medical advice.


Short answer: Most people regain a significant portion of lost weight after stopping a GLP-1 medication. A 2022 STEP 1 extension found roughly two-thirds of lost weight returned within a year of stopping semaglutide. In a 39-person pilot trial, people given a wellness app or medically tailored meals gained less weight over four months than usual care — an exploratory result the authors say needs larger trials. Individual variation is substantial.

Updated November 6, 2026


Key Facts

  • ~⅔ of lost weight returned within one year of stopping semaglutide 2.4mg in the STEP 1 extension: participants regained a mean 11.6 percentage points of body weight (from −17.3% at week 68 to −5.6% at week 120, one year after stopping) — Wilding JPH et al., Diabetes, Obesity and Metabolism, 2022. PMID 35441470
  • A 2026 pilot RCT tested three approaches at the moment of GLP-1 discontinuation (n=39, 4 months): usual care, a digital wellness app, and medically tailored meals. The primary outcomes — adherence and satisfaction — did not differ significantly between groups. The weight finding (both intervention arms showed approximately 7% less weight gain than usual care, exploratory) was not a primary endpoint and the authors call for larger trials — Hollis-Hansen K et al., Obesity Science & Practice, published October 7, 2026. PMID 42846130. DOI 10.1002/osp4.70194

For background on what regain looks like across the broader literature, see GLP-1 Weight Regain After Stopping: Real Data.


What the Evidence Shows

Why regain happens

GLP-1 receptor agonists suppress appetite and slow gastric emptying by activating GLP-1 receptors in the gut and brain. When the drug stops, those signals stop. Hunger returns, and without the drug-mediated suppression, caloric intake often increases.

What the STEP 1 extension showed

The STEP 1 extension (Wilding et al., PMID 35441470) followed participants for one year after stopping semaglutide 2.4mg. By week 120 (one year post-stop), mean body weight had returned to −5.6% from baseline — compared with −17.3% at the end of active treatment at week 68. Cardiometabolic risk markers also moved back toward pre-treatment values.

This is the most cited dataset on the subject. It reflects group averages; individual outcomes varied considerably.

What the 2026 pilot RCT showed

The Tufts Food is Medicine Institute pilot (Hollis-Hansen et al., PMID 42846130) randomized 39 adults to three arms at the moment of GLP-1 discontinuation. The study's primary outcomes were adherence and satisfaction — and those did not differ significantly between groups.

The exploratory weight finding: both the wellness app arm and the medically tailored meals arm showed approximately 7% less weight gain than usual care at 4 months. The authors describe this as a signal justifying larger trials, not a confirmed clinical finding. Four months is a short follow-up, and the study was not powered to establish effect sizes.


If You're on or Coming Off a GLP-1

If you're planning to stop a GLP-1, talk to your prescriber before you stop.

Current clinical guidance recommends adequate protein and progressive resistance training to preserve lean mass during weight loss (Mozaffarian D et al., Am J Clin Nutr 2025, PMID 40450457). Whether they reduce regain after stopping a GLP-1 has not been established in trials.

Nothing in this post is a treatment recommendation, a dosing instruction, or a promise about outcomes. Individual results vary substantially.


Sources

  • Wilding JPH et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide." Diabetes, Obesity and Metabolism, 2022. PMID 35441470
  • Hollis-Hansen K et al. "Preventing Weight Regain After GLP-1 Therapy Discontinuation: A Pilot Randomized Controlled Trial." Obesity Science & Practice, published October 7, 2026. PMID 42846130. DOI 10.1002/osp4.70194
  • Mozaffarian D et al. Am J Clin Nutr. 2025;122(1):344–367. PMID 40450457
  • Background data: GLP-1 Weight Regain After Stopping: Real Data

Keep reading with The Peptides Brief

One email a week on what the evidence actually says. No dosing, no hype.

Unsubscribe anytime · Privacy